<DOC>
	<DOCNO>NCT02555735</DOCNO>
	<brief_summary>This observational study enrol patient metastatic pancreatic cancer identify genomic difference exceptional responder non-responders standard care chemotherapy . Data analysis gene expression profile exceptional responder compare non-responders define genomic pattern may help understand response chemotherapy .</brief_summary>
	<brief_title>Exceptional Responders With Pancreatic Cancer Chemotherapy</brief_title>
	<detailed_description>This observational study patient metastatic pancreatic cancer identify genomic difference obtain circulate tumor cell exceptional responder non-responders standard care chemotherapy . This study require 10 mL heparinized peripheral blood sample study participant time enrollment isolate , enrich profile circulate tumor cell . Data analysis gene expression profile define genomic pattern use Nearest Template Prediction predetermine panel therapeutic agent base standard care . Chemotherapy selection physician-choice . Information regard disease progression gather . Data analysis perform study participant set ongoing disease progression .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histological cytological confirmation metastatic pancreatic adenocarcinoma . Patient treatmentna√Øve currently receive frontline chemotherapy FOLFIRINOX GEMCITABINEABRAXANE stable disease . ECOG performance status 02 . Patients must hemoglobin 7.5 g/dl great hemodynamically stable and/or physiologically compensate anemia HIV positive antiretroviral therapy Disease progression follow frontline chemotherapy Pregnant lactate Prior organ allograft Any medical psychiatric condition may interfere ability comply protocol treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>